Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

Shinya Kimura, Jun Imagawa, Kazunori Murai, +24

The Lancet Haematology

Hematological MalignancyMedicineFirst-line Dadi TrialChronic Myeloid LeukaemiaHematology +7

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

Kazunori Murai, Hiroshi Ureshino, Takashi Kumagai, +11

The Lancet Haematology

Chronic PhaseLow-dose DasatinibHematological MalignancyOncologyHematology +6

Clinical impact of the CONUT score in patients with multiple myeloma

Sho Okamoto, Hiroshi Ureshino, Keisuke Kidoguchi, +16

Annals of Hematology

Hematological MalignancyHealth SciencesMedicineHematologyConut Score +5

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

Tatsuro Watanabe, Satoshi Yamashita, Hiroshi Ureshino, +14

Blood

Allelic Polymorphisms of <i>KIR</i> s and <i>HLA</i> s Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML

Hiroshi Ureshino, Takero Shindo, Hiroto Kojima, +6

Cancer Immunology Research

Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia

Hiroshi Ureshino, Takero Shindo, Hiroyoshi Nishikawa, +15

Cancer Immunology Research

Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma

Hiroshi Ureshino, Kana Kusaba, Keisuke Kidoguchi, +11

Annals of Hematology

Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyConut Score +4

Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors

Sho Okamoto, Hiroshi Ureshino, Atsushi Kawaguchi, +3

International Journal of Hematology

Chronic Myeloid LeukemiaUrologyRenal FunctionMedicineKidney Failure +10

Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL

Yuki Kurahashi, Tatsuro Watanabe, Yuta Yamamoto, +11

Blood Advances

Histone ModificationsMixed-phenotype Acute LeukemiaEpigenetic ChangeDna MethylationImmunology +18

Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia

Kazuharu Kamachi, Hiroshi Ureshino, Tatsuro Watanabe, +10

Cancer Letters

Mixed-phenotype Acute LeukemiaLow Tkis SensitivityTumor BiologyMyeloid NeoplasiaHematological Malignancy +14